Department of Radiology (TDA, MAF, MRC, JWC), Mayo Clinic, Rochester, Minnesota.

We determined technical feasibility, safety and short-term outcomes following percutaneous renal cryoablation.

We performed a retrospective review of 115 renal tumors in 110 patients treated with percutaneous cryoablation. Specific attention was directed to tumor characteristics, hospital course, complications, technical success and treatment success based on followup imaging.

Mean tumor size was 3.3 cm (range 1.5 to 7.3), including 29 tumors 4.0 cm or larger and 21 tumors in the anterior kidney. Of 90 renal mass biopsies performed 52 (58%) showed renal cell carcinoma. All patients were admitted to the hospital following cryoablation and most (87%) were discharged home the next day (range 1 to 12 days). There were 7 major complications associated with the 113 cryoablation procedures (6%). Technical success was achieved in 112 of the 115 (97%) treated tumors and 3 residual tumors were seen on 3 month followup imaging. In 80 tumors followed 3 months or longer (mean 13.3 months) There has been no local progression of (100% treatment success).

Percutaneous renal cryoablation is technically feasible and relatively safe. With experience many anterior tumors and tumors larger than 4 cm can be successfully treated. Long-term followup remains necessary to prove treatment durability.

Written by
Atwell TD, Farrell MA, Leibovich BC, Callstrom MR, Chow GK, Blute ML, Charboneau JW.

Reference
J Urol. 2008 Apr 16. Epub ahead of print.
doi:10.1016/j.juro.2008.01.144

PubMed Abstract
PMID:18423719

UroToday.com Renal Cancer Section

Please log-in or register in order to submit comments.

Powered by AkoComment!